1. Introduction {#sec0005}
===============

The influenza viruses are a leading cause of respiratory illness in humans and are responsible for annual seasonal outbreaks that have serious economic impact. In addition, the wide host range of the virus and the potential for genome reassortment between human influenza viruses and those of other species mean these viruses present a pandemic threat. To establish a productive infection and thus cause disease, influenza viruses must overcome host innate immune responses that are very rapidly activated during infections. The interferon (IFN) family of antiviral cytokines play a major role in these responses and are critical in restricting the early stages of virus infections prior to the activation of the adaptive immune system. The IFNs and other innate immune mediators have serious implications for the outcome of influenza virus infections in terms of disease severity, since highly pathogenic viruses are often associated with excessive cytokine responses ([@bib0025], [@bib0365]). In this review, we summarise recent developments in our understanding of how influenza viruses activate the IFN system and highlight areas in which this understanding is still incomplete.

2. The interferon response to influenza virus {#sec0010}
=============================================

The IFNs are expressed and secreted following the detection of viral components within infected cells; subsequent binding of IFN to its cognate receptor at cell surfaces leads to the upregulation of hundreds of different interferon-stimulated genes (ISGs) that establish an 'antiviral state' to efficiently limit further replication and spread of the virus (reviewed in [@bib0670]). Of these ISGs, several have been identified as having direct anti-influenza virus activity. These include the Mx family of GTPases, which are thought to form oligomeric rings around viral nucleocapsids to inhibit their nuclear import and/or replication ([@bib0225], [@bib0265], [@bib0645], [@bib0805], [@bib0885], [@bib0915]); viperin, which affects virus budding and thus limits the release of viral particles from infected cells ([@bib0855]) (although the contribution of viperin to the restriction of influenza virus replication in vivo is less clear-cut, [@bib0785]); and the IFN-induced transmembrane (IFITM) family members (in particular IFITM3), which interfere with fusion between viral and endosomal membranes thereby limiting viral entry ([@bib0050], [@bib0115], [@bib0165], [@bib0170], [@bib0475]).

The IFNs are classified into three types according to their amino acid sequence and the type of receptor through which they signal. The type I IFNs (which include multiple IFN-α subtypes and IFN-β) and the type III IFNs (IFN-λ) are directly upregulated following virus infection; these are the major IFNs secreted following influenza virus infections in vitro and in vivo ([@bib0100], [@bib0315], [@bib0325], [@bib0385], [@bib0850]). In contrast, type II IFN (IFN-γ) is secreted by activated T lymphocytes and NK cells and will not be discussed further in this review. Airway epithelial cells, plasmacytoid dendritic cells (pDCs) and macrophages are the main producers of IFN during influenza virus infections ([@bib0085], [@bib0290], [@bib0315], [@bib0330], [@bib0350], [@bib0355]). Several studies suggest that airway epithelial cells are primarily responsible for type III IFN production while dendritic cells and alveolar macrophages are the major source of type I IFNs ([@bib0315], [@bib0385], [@bib0850]). The induction of both type I and type III IFNs in virus-infected epithelial cells is thought to occur in response to the same viral ligands and via the same signalling components ([@bib0100], [@bib0615]); furthermore, the panel of ISGs upregulated in airway epithelia in response to type I and type III IFNs following influenza virus infection shows complete overlap ([@bib0100]). However, while the type I IFN receptor is expressed at the surface of all cells, expression of the type III IFN receptor is primarily restricted to epithelial cells in the respiratory and gastrointestinal tracts ([@bib0570], [@bib0755]). During an influenza virus infection, it is possible that this differential expression of the type III IFN receptor functions to elicit an antiviral response in airway epithelia while restricting the activation of immune cells and associated lung pathology ([@bib0290]).

The IFN induction cascade becomes stimulated following the recognition of certain molecular structures that are absent in uninfected cells, termed pathogen-associated molecular patterns (PAMPs). For RNA virus infections, these PAMPs are predominantly certain features of viral RNA that are not usually present in cellular RNAs, such as regions of double-stranded RNA (dsRNA) or the presence of a 5′-triphosphate (5′ppp) or a 5′-diphosphate (5′pp) group. The pathogen-recognition receptors (PRRs) play a critical role in the distinction of self from non-self molecules by binding to PAMPs within infected cells. Two types of PRRs have been implicated in the induction of IFNs by influenza viruses, with the role of a particular PRR depending on the cell type and nature of the viral stimuli. The Toll-like receptor (TLR) family of transmembrane proteins are able to recognise a wide range of microbial ligands, and signal downstream through either MyD88 (myeloid differentiation primary response 88) or TRIF (Toll-interleukin-1 receptor (TIR)-domain-containing adaptor inducing interferon (IFN)-β) adaptor proteins to stimulate IFN expression, depending on the particular TLR (reviewed in [@bib0470]). TLR7 is a receptor for ssRNA and recognises incoming virions in endosomal compartments during influenza virus infection of pDCs ([@bib0125], [@bib0505]); it is consequently required for the production of high levels of type I IFNs by these cells ([@bib0125], [@bib0355], [@bib0505]). In other cell types, TLR7 is dispensable for IFN induction by RNA viruses including influenza virus ([@bib0370], [@bib0435], [@bib0895]), either because it is not expressed ([@bib0555]) or because its localisation is non-endosomal ([@bib0315]). TLR3 recognises dsRNA and is also activated by influenza virus infection ([@bib0455]). However, although TLR3 contributes to IFN induction by other viruses (reviewed in [@bib0470]), TLR3-deficient airway epithelial cells and pDCs have normal type I IFN responses to influenza virus infection ([@bib0125], [@bib0455]); instead, TLR3 in the context of influenza virus infections functions to activate pro-inflammatory signalling pathways ([@bib0255], [@bib0455]).

Non-self RNAs in the cytoplasm are detected by a second group of PRRs, the cytosolic RIG-I-like receptors (RLRs), consisting of RIG-I, MDA-5 and LGP2. These receptors are essential for IFN induction during RNA virus infections of non-pDC cell-types, and mice that are deficient in RLR signalling pathways are extremely susceptible to RNA viruses despite possessing intact TLR systems ([@bib0380], [@bib0440], [@bib0775]). Both RIG-I and MDA-5 contain two caspase activation and recruitment domains (CARDs) at their N-terminus, an RNA helicase domain possessing dsRNA-dependent ATPase activity and a C-terminal regulatory domain (CTD). Ligand binding to the CTD and the helicase domain induces a conformational change in the RLRs that exposes the CARDs ([@bib0430], [@bib0500], [@bib0510], [@bib0865]). Activity following ligand binding is modulated by the posttranslational modification of the CARDs by dephosphorylation and/or ubiquitination (reviewed in [@bib0210]). For example, TRIM25, RIPLET and/or MEX3C-dependent Lys63-linked ubiquitination of the CARDs occurs following ligand binding to RIG-I ([@bib0220], [@bib0445], [@bib0620], [@bib0625]). Additionally, free Lys63 polyubiquitin chains have been reported to bind RIG-I and MDA-5 CARDs and stimulate activity ([@bib0905]). Downstream signal transduction occurs by the CARD-dependent association of RIG-I/MDA-5 with the mitochondrial antiviral signalling protein (MAVS) at the outer mitochondrial membrane. This interaction promotes MAVS oligomerisation and the assembly of large multiprotein complexes that activate NF-κB and the IFN regulatory factors (IRF3 or IRF7, depending on the IFN subtype, [@bib0635]) to stimulate expression of type I and type III IFNs. LGP2 has a similar structure to RIG-I and MDA-5 but lacks the CARDs; this protein has thus been implicated in the regulation of RIG-I and MDA-5 activity ([@bib0095], [@bib0705], [@bib0715]).

RIG-I and MDA-5 each recognise different types of viral RNA, with RIG-I most efficiently activated by short stretches of 5′ppp or 5′pp dsRNA while MDA-5 is activated by longer stretches of dsRNA in a 5′ phosphate-independent manner; these PRRs have therefore been shown to recognise different families of RNA viruses ([@bib0380], [@bib0495]). Knockdown studies have shown that IFN induction in response to influenza virus infection is predominantly mediated through RIG-I ([@bib0380], [@bib0495]), and influenza virus-induced IFN expression in airway epithelial cells, the primary site of influenza virus replication, is RIG-I-dependent ([@bib0455]). MDA-5 may still contribute to IFN induction by influenza viruses however, since small reductions in IFN induction and ISG responses can be seen in infected MDA-5-deficient cells compared to control cells ([@bib0310], [@bib0380], [@bib0495]). Moreover, type I IFNs are still produced following influenza virus infection or transfections of influenza RNA in chicken cells, which lack RIG-I ([@bib0360], [@bib0490]). Instead, IFN induction in this system is mediated through MDA-5 ([@bib0490]).

3. Influenza virus replication {#sec0015}
==============================

The influenza virus genome is composed of eight different segments of single-stranded negative-sense viral RNA (vRNA) that exists in virions in the form of viral ribonucleoproteins (vRNPs) which are the minimum units required for viral transcription and replication ([@bib0745]). vRNPs are held in a closed circular conformation by the binding of the trimeric viral RNA-dependent RNA polymerase to the partially complementary 5′ and 3′ termini of the vRNA, with the remainder of the vRNA segment bound along its length by viral nucleoprotein (NP) oligomers (reviewed in [@bib0680]). Following binding of virions to sialic acid-containing receptors on the surface of host cells, virus particles are taken into the cell by endocytosis followed by vRNP release into the cytoplasm and import to the nucleus, where they serve as the templates for viral transcription and replication. vRNPs are first transcribed by the vRNP-associated polymerase in a reaction primed by 5′ capped 10--13nt RNAs that are derived from cellular pre-mRNAs through the polymerase cap-binding and endonucleolytic activities (reviewed in [@bib0185]). Viral mRNA synthesis is therefore dependent on the activity of host RNA polymerase II and can thus be inhibited by drugs that target cellular transcription ([@bib0065], [@bib0280], [@bib0540], [@bib0845]). The viral polymerase is also responsible for polyadenylating the 3′ end of viral transcripts, following which they are exported to the cytoplasm for viral protein expression. Replication of the influenza virus genome occurs through the synthesis of full-length complementary copies of the vRNA, the complementary RNA (cRNA). cRNAs are also encapsidated into cRNPs, which in turn act as the template for the polymerase-directed synthesis of progeny vRNPs. Since genome replication is an unprimed reaction and occurs de novo, influenza virus vRNAs and cRNAs possess a 5′ppp.

4. Evasion of PRR recognition by influenza viruses {#sec0020}
==================================================

If naked cRNAs and vRNAs were generated during the replication of the influenza virus genome, cRNA:vRNA hybridisation would lead to the formation of RIG-I and MDA-5 ligands, activation of the IFN response and restriction of virus replication. To avoid this, influenza virus employs strategies to evade detection by RLRs, thus allowing the virus to replicate efficiently without inducing IFN. Firstly, unlike other RNA viruses that replicate exclusively in the cytoplasm, influenza virus transcription and replication is nuclear. Since RIG-I and MDA-5 are confined to the cytoplasm, nuclear genome replication means that cRNA and progeny vRNAs are generated at a site that is inaccessible to these PRRs. Secondly, the synthesis of full-length cRNA from vRNA and vice versa is very closely coupled to encapsidation; the interaction between the first nucleoprotein monomer and polymerase at 5′ end of the RNA is thought to nucleate the sequence-independent encapsidation of the nascent RNA ([@bib0890]). Consequently, NP is required for full-length genome amplification ([@bib0295], [@bib0560], [@bib0740], [@bib0845]). This process also appears to involve cellular factors, since UAP56 and Tat-SF1 interact with NP to promote viral RNA encapsidation ([@bib0565], [@bib0580]). Thus, nascent full-length cRNA and vRNA molecules do not exist as 'free' RNA and the formation of cRNA:vRNA hybrids is prevented. Consistent with this, long dsRNAs are undetectable during influenza virus infections ([@bib0045], [@bib0375], [@bib0660], [@bib0870]) and the knockdown of UAP56 leads to an accumulation of dsRNA in infected cells ([@bib0880]). Thirdly, influenza virus encodes antagonists of the IFN system (reviewed in [@bib0230]). The principal of these is the NS1 protein, which targets multiple components of the IFN induction cascade to limit IFN expression (reviewed in [@bib0160], [@bib0260]). NS1 sequesters dsRNA to limit activation of RLRs ([@bib0140], [@bib0760]), targets TRIM25 to inhibit RIG-I activation ([@bib0215]) and in some influenza virus strains, limits IFN expression post-transcriptionally by interfering with the processing and nuclear export of cellular mRNAs ([@bib0200], [@bib0285], [@bib0590], [@bib0605], [@bib0720]). Other viral proteins have also been described as having IFN-antagonistic properties, including PB1-F2 ([@bib0145], [@bib0820]) and the viral polymerase ([@bib0250], [@bib0320], [@bib0835]). Nuclear replication, efficient encapsidation of cRNA and vRNA, and IFN antagonism by viral proteins are very effective at preventing activation of the IFN system during infection: studies examining IFN induction in individual cells infected with a range of strains of influenza A virus found that the IFN-β promoter had only been activated in a small proportion of infected cells, both in vitro and in vivo ([Fig. 1](#fig0005){ref-type="fig"}) ([@bib0070], [@bib0350]). Furthermore, activation of the IFN response could not be detected within some developing influenza virus plaques in lung epithelial cells ([@bib0070]). This may also be the case for influenza viruses that do not express a functional NS1 protein and therefore lack the principal viral IFN antagonist. Such viruses are known to be better inducers of IFN than wild-type viruses ([@bib0155], [@bib0235], [@bib0415], [@bib0860]), yet [@bib0350] demonstrated IFN-β promoter activation in only a fraction of infected cells within the lung epithelia of IFN-β reporter mice infected with a virus lacking the NS1 gene. Thus, the elevated IFN expression induced by this and other NS1-defective viruses relative to wild-type virus is likely to be due to a subset of infected cells (as has been observed for cells infected with a paramyxovirus lacking an IFN antagonist, [@bib0405]), and this is sufficient for the establishment of an antiviral state that impairs the replication of these viruses in IFN-competent systems ([@bib0155], [@bib0235]). The reasons for this cell-to-cell variation in IFN-β promoter activation by influenza are not yet fully resolved, but may be dictated by differences in the nature of the infecting virus particles (i.e. the presence of defective interfering \[DI\] viruses, which will be discussed later in this review, [@bib0035], [@bib0070], [@bib0405], [@bib0790]), the host cell ([@bib0665], [@bib0910]), or indeed a combination of both, depending on the cell system and the virus used.

5. In vitro RIG-I ligands {#sec0025}
=========================

Several different types of RNA have been identified as ligands for RIG-I in the literature (reviewed in [@bib0725]). The presence of a triphosphate at the 5′ end of RNA is now generally accepted as a particularly important characteristic in a RIG-I ligand ([@bib0300], [@bib0430], [@bib0500], [@bib0865]), although it has been demonstrated recently that RIG-I can additionally trigger IFN induction in response to RNA bearing 5′-diphosphates ([@bib0245]). Other features such as double-strandedness, length and A/U composition can also define the ability of RNA to induce IFN through RIG-I, irrespective of 5′ phosphates ([@bib0040], [@bib0110], [@bib0275], [@bib0375], [@bib0520], [@bib0525], [@bib0695], [@bib0710], [@bib0815]). Although early studies suggested that in vitro transcribed 5′ppp single-stranded RNA (ssRNA) could induce IFN through RIG-I ([@bib0300], [@bib0410]), these results are now thought to be due to the generation of unexpected basepaired RNA products in *in vitro* transcription reactions, in addition to the expected ssRNA transcript ([@bib0060], [@bib0730]). More recent studies showed that there is a requirement for a region of blunt dsRNA directly adjacent to the 5′ppp ([@bib0725], [@bib0730]); these have since been backed up by structural studies ([@bib0425], [@bib0430], [@bib0500]). The minimum length of the double-stranded region required to give 5′ppp-dependent IFN induction has been shown to range from 10 basepairs (bp) ([@bib0420], [@bib0730]) to at least 19 bp ([@bib0725]). Within this short dsRNA stretch, there has been shown to be some tolerance of wobble base-pairs, bulges and mismatches, as found in the 'panhandle' genome structures of single-stranded negative-sense RNA viruses ([@bib0545], [@bib0725]). It is noteworthy that there are a number of RNA structures, including 5′OH dsRNAs and 5′ppp dsRNAs with overhanging nucleotides, that can bind to RIG-I yet do not stimulate IFN induction ([@bib0275], [@bib0500], [@bib0545], [@bib0730], [@bib0780]). Indeed, dsRNA with a single overhanging 5′ppp nucleotide, such as those found in some arenavirus genomes, can potently inhibit IFN-β induction by a blunt-ended 5′ppp dsRNA, presumably by competing with blunt-ended 5′ppp dsRNA for RIG-I binding ([@bib0545]).

6. The influenza virus 'panhandle' as a RIG-I inducer {#sec0030}
=====================================================

The 5′ and 3′ termini of the influenza virus genome segments contain sequences of 13 and 12 nucleotides (nt) respectively that are highly conserved across segments and virus subtypes (with the exception of a U4C variation in the 3′ terminus of some genome segments) ([@bib0120], [@bib0690]). These sequences possess a partial inverted complementarity, and the influenza virus vRNA segments consequently have the potential to form a 'panhandle' structure ([Fig. 2](#fig0010){ref-type="fig"}A) that is believed to act as the vRNA promoter ([@bib0190], [@bib0305], [@bib0795]). NMR, FRET and enzymatic studies of short naked RNAs corresponding to the 3′ and 5′ termini have demonstrated the formation of a stable partial duplex of approximately 15 bp in length between the conserved termini and two to three additional segment-specific bases, through Watson--Crick and non-Watson--Crick basepairing ([Fig. 2](#fig0010){ref-type="fig"}A) ([@bib0015], [@bib0030], [@bib0075], [@bib0080], [@bib0305], [@bib0610], [@bib0800]). Thus, the influenza virus panhandle has been suggested to be able to act as a potent RIG-I ligand by virtue of the 5′ppp being directly adjacent to a small stretch of partially double-stranded RNA. Although neither the formation of a panhandle structure within a full-length genome segment nor the contribution of terminal base-pairing to IFN induction by influenza virus have yet been directly demonstrated, *in vitro* transcription products corresponding to influenza virus segments are able to induce IFN when transfected into cells ([@bib0035], [@bib0630]) suggesting that the influenza virus vRNAs possess an inherent ability to induce IFN. The observations that RNA extracted from influenza virus-infected cells, from purified influenza virions or from RNP reconstitutions activate the IFN response when transfected into cells in a RIG-I-dependent manner ([@bib0090], [@bib0375], [@bib0630], [@bib0660], [@bib0675]) have also been used as evidence for IFN induction by the influenza panhandle. IFN induction by RNA extracted from infected cells is unaffected by RNase III treatment, which digests long dsRNAs into short fragments of 12--15 bp ([@bib0375]). This may be considered further support for IFN induction by the panhandle, since the base-paired stem would presumably be too short in length to be targeted by this enzyme.

While short free RNAs with the conserved 3′ and 5′ terminal sequences of vRNA forms a panhandle structure ([@bib0015], [@bib0030], [@bib0075], [@bib0080], [@bib0305], [@bib0610], [@bib0800]), evidence suggests that encapsidated polymerase-bound vRNA does not. Polymerase binding to the vRNA termini causes the formation of a secondary structure, the 'corkscrew' conformation, which has been shown by several studies to be critical for viral polymerase activity ([@bib0055], [@bib0175], [@bib0180], [@bib0460], [@bib0465]). In this structure, the very ends of the 5′ and 3′ termini do not associate but instead form intra-termini hairpin loops ([Fig. 2](#fig0010){ref-type="fig"}B) ([@bib0180]). A highly sensitive single-molecule FRET assay was recently used to examine changes in the structure of short RNAs corresponding to the 5′ and 3′ termini of the genome segments. These RNAs form a partial dsRNA structure in the absence of viral polymerase but undergo a polymerase-dependent conformational change that is consistent with the formation of the corkscrew ([@bib0800]). The termini of free vRNA therefore form a dsRNA panhandle that is recognised and bound with high affinity by the viral polymerase, causing the vRNA to adopt the corkscrew conformation. Although the corkscrew permits some inter-strand basepairing, this structure would be unlikely to activate RIG-I since the terminal nucleotides do not bind each other to form dsRNA ([@bib0175], [@bib0195]). Furthermore, recent structural determination of an influenza A virus polymerase in complex with the vRNA promoter appears to be incompatible with RIG-I binding of polymerase-associated RNA, since the 5′ppp end of the vRNA is buried within the polymerase in a pocket formed by PA and PB1 ([@bib0655]). In order for an influenza virus genome segment to activate RIG-I therefore, it is likely to exist in the panhandle conformation, which is suggestive of a free, unencapsidated RNA.

The number of vRNA molecules within an infected cell vastly outnumbers cRNA, with the proportion of vRNAs to cRNAs estimated at between 10:1 and 40:1, depending on the segment ([@bib0270], [@bib0575]). For this reason, much of the work on influenza virus RNA and IFN induction has focused on the vRNA. Given that the cRNA is an exact complement of the vRNA, the cRNA termini are also partially complementary and would thus be expected to form panhandle and corkscrew structures. Indeed, cRNPs form closed helical loop structures similar to vRNPs ([@bib0900]) and the formation of a corkscrew structure by the cRNA termini has been demonstrated ([Fig. 2](#fig0010){ref-type="fig"}C) ([@bib0010], [@bib0105]). It is possible that structural differences exist between the vRNA and cRNA promoter structures however, since the wobble basepairs at positions 3 and 5 in the vRNA promoter become mismatched in the cRNA promoter; indeed, the structure of the cRNA promoter has been suggested to be more unstable than that of the vRNA ([@bib0640]) so cRNA and vRNA may differ in the efficiency with which they activate RIG-I.

7. Identification of natural influenza virus PAMPs {#sec0035}
==================================================

7.1. Identification of RIG-I ligands from infected cells {#sec0045}
--------------------------------------------------------

Naked viral RNAs generated by *in vitro* transcription reactions or by RNA extractions from infected cells have been shown to induce IFN, yet such free RNAs would not be expected to be generated during virus infections due to vRNA and cRNA encapsidation. Two studies therefore addressed the nature of the 'genuine' viral PAMPs responsible for activating RIG-I during influenza virus infections. [@bib0035] immunoprecipitated RIG-I from cells infected with an NS1-deficient virus, extracted RIG-I-associated RNA and performed deep sequencing analyses to identify RIG-I ligands. Although sequences mapping to all genome segments could be detected in RIG-I immunoprecipitates, there was particular enrichment for reads mapping to the smallest viral segments M and NS. Furthermore, reads mapping to the PA and PB1 polymerase segments were particularly over-represented in the 5′ and 3′ regions, which is highly suggestive of RNAs derived from genome segments containing large internal deletions. This analysis did not determine whether the RIG-I associated RNAs were vRNA, cRNA or mRNA in nature, since the amplification method used did not permit the retention of strand orientation information.

[@bib0675] used a different approach to address the same question. The authors demonstrated the formation of a trimolecular complex of RIG-I, an in vitro RNA transcript and NS1, and by purifying this complex, RNA with IFN-inducing activity could be isolated. A similar complex was postulated to form with the bona fide RIG-I agonist during influenza virus infection, permitting genuine PAMPs from infected cells to be co-precipitated with the NS1 protein. Consistent with this, RNA purified from NS1-immunoprecipitates induced expression from an IFN-β reporter gene in a RIG-I- and 5′ppp-dependent manner, and NS1-associated RNA was enriched for full-length vRNA from all eight segments (in addition to cRNA and mRNA from some segments). Furthermore, RIG-I immunoprecipitates also contained full-length vRNA and cRNA, supporting the authors' conclusions that full-length genomes constitute the major PAMP in infected cells.

The identification of influenza virus RNA, and in particular vRNA, as ligands of RIG-I in these studies is not surprising, given that the vRNA panhandle possesses the characteristics required for RIG-I activation. What remains to be determined however is how the vRNA panhandle structure is able to form in infected cells, since replication of the virus genome is so closely coupled to encapsidation of the nascent RNA. Two scenarios can be envisaged regarding RIG-I activation during influenza virus infections. The first is that free vRNA, forming a panhandle, is generated erroneously at some point in a virus infection; if this is the case, when and how is this free RNA species generated? The second is that RIG-I can somehow recognise vRNA within the context of a vRNP. Since the polymerase obscures the genome termini, the latter of these scenarios would presumably require displacement of the polymerase from the vRNA promoter for RIG-I recognition. Interestingly, the individual polymerase subunits have been found to associate with RIG-I in an RNA-independent manner ([@bib0480]); although these associations were not found to have clear implications for activation of the IFN response, it is possible that RIG-I recruitment to the vRNP through polymerase interactions could induce a conformational change in the vRNP structure that leads to formation and exposure of the panhandle.

7.2. The requirements for transcription and replication {#sec0050}
-------------------------------------------------------

Since influenza viruses replicate in the nucleus and RIG-I resides in the cytoplasm, incoming and progeny genomes traversing the cytoplasm are the most obvious candidates for triggering IFN induction, and there is some debate about the contribution of each of these to RIG-I activation by influenza viruses. Full-length genome replication requires ongoing viral protein synthesis due to the requirement for concurrent encapsidation by NP and newly synthesised polymerase ([@bib0295], [@bib0345], [@bib0740], [@bib0840], [@bib0900]); the translation inhibitor cycloheximide therefore prevents cRNP and progeny vRNP accumulation (and subsequently secondary viral transcription) in infected cells ([@bib0020], [@bib0270], [@bib0840]). [@bib0675] reported that no RNA capable of stimulating the IFN-β promoter could be extracted from infected cells in the presence of cycloheximide. Furthermore, they used an RNP reconstitution method to demonstrate IFN induction by reconstitutions with a transcription-defective but not a replication-defective viral polymerase and thus concluded that viral genome replication was required to stimulate IFN expression ([@bib0675]). However, recent studies have demonstrated IRF3 activation and transcription of both IFN-β and ISG56 genes in conditions where progeny vRNA synthesis is inhibited, either by cycloheximide treatment or using siRNA to NP ([Fig. 3](#fig0015){ref-type="fig"}) ([@bib0390], [@bib0630], [@bib0875]).

Incoming viral nucleocapsids have been implicated in RIG-I activation by members of the Bunyaviridae, which also possess segmented negative-sense RNA genomes with a 5′ppp panhandle structure ([@bib0875]); activation of the IFN induction cascade in the presence of cycloheximide would be consistent with this also being the case for influenza virus infections. Indeed, a recent study has reported the association of vRNPs with RIG-I and MAVS at the mitochondrion at 3 h post-infection ([@bib0485]). However, several studies have indicated that incoming influenza A vRNPs are not sufficient to induce IFN during infection of epithelial cells and monocyte-derived DCs (moDCs), and that viral RNA synthesis is required ([@bib0100], [@bib0390], [@bib0630]). Efficient inhibition of IRF3 and NF-kB activation by the cellular transcription inhibitors actinomycin D and alpha-amanitin in influenza-infected cells strongly suggests that incoming genomes do not function as a major PAMP in lung epithelial cells ([Fig. 3](#fig0015){ref-type="fig"}) ([@bib0390]). These drugs do not affect the transport of incoming vRNPs to the nucleus, but potently inhibit viral transcription (because of the requirement for cellular transcripts for priming viral mRNA synthesis) and cRNP and vRNP generation (due to inhibition of de novo NP and polymerase synthesis). Virus-mediated IRF3 activation is also inhibited by 5,6-dichloro-1-β-d-ribofuranosyl-benzimidazole (DRB) treatment ([@bib0390]), which permits viral transcription but impedes the export of viral transcripts from the nucleus ([@bib0005], [@bib0065]). The effects of these drugs on IRF3 activation were specific to influenza viruses, since they have no effect on activation of the IFN induction cascade by the dsRNA analogue poly(I:C) or by paramyxoviruses ([Fig. 3](#fig0015){ref-type="fig"}) ([@bib0390]) which replicate in the cytoplasm and do not rely on cellular transcription ([@bib0450]). Moreover, expression of type I and type III IFNs following influenza A virus infection correlates with the accumulation of viral RNAs ([@bib0630]) and can be completely abrogated following inactivation of the virus by heat or UV treatment ([@bib0100], [@bib0630]). The above studies have been limited to a relatively small number of influenza A virus strains, so it is conceivable that different influenza A virus strains may vary in their capacity to be recognised by RIG-I during vRNP entry. Interestingly, influenza B viruses elicit a much more rapid activation of IRF3 than influenza A virus and this activation is insensitive to UV treatment ([@bib0630]) indicating that the incoming genomes of these different virus genera may differ in their ability to be recognised by PRRs.

Taken together, these observations strongly suggest that the generation of the major influenza A virus PAMPs requires the synthesis and nuclear export of an RNA product or products from incoming genomes, and that these RNAs can be generated even in conditions where cRNP and vRNP accumulation is impaired. Nevertheless, it is likely that distinct PAMPs are generated at different stages of the virus life cycle; thus, a minority of incoming influenza A virus genomes may contribute to IFN induction at very early points post-infection, with viral polymerase products (including, but not limited to, progeny genomes) functioning as a more significant PAMP population later in infection. The nature of the PAMPs that are generated in the presence of cycloheximide but not in the presence of cellular transcription inhibitors has not yet been elucidated, and although the sensitivity of IRF3 activation to viral transcription inhibitors may superficially suggest that viral mRNAs can function as IFN inducers, the fact that influenza virus mRNAs are 5′ capped and polyadenylated like host mRNAs makes this unlikely. Moreover, viral mRNAs cannot be detected in RIG-I immunoprecipitations from infected cells, the immunostimulatory activity of RIG-I associated RNA is sensitive to calf intestinal phosphatase treatment (which removes 5′ phosphates), and RNA capable of inducing IFN is still generated in RNP reconstitutions containing a transcription-defective viral polymerase ([@bib0675]). It is of note that actinomycin D and alpha-amanitin can also affect the nucleocytoplasmic export of viral mRNAs ([@bib0005], [@bib0390], [@bib0515]) so may also affect export of other viral RNA species; in actinomycin D and alpha-amanitin treatment conditions therefore, viral PAMPs may be retained in the nucleus and thus hidden from RIG-I. It has been suggested that cRNA synthesis from input vRNP templates does not require viral protein synthesis for the initiation of replication per se, but that *de novo* synthesised polymerase and NP are required to stabilise the cRNA and prevent its degradation by host nucleases ([@bib0840], [@bib0845]). Unencapsidated, unstable cRNAs would therefore be expected to be generated in conditions where polymerase and NP synthesis has been blocked by transcription or translation inhibitors, and these RNAs may be able to activate RIG-I if they were able to reach the cytoplasm.

7.3. Defective genomes and IFN induction by influenza virus {#sec0055}
-----------------------------------------------------------

The observations that influenza viruses only activate the IFN response in a fraction of infected cells with both wild-type and NS1-defective viruses ([Fig. 1](#fig0005){ref-type="fig"}) ([@bib0070], [@bib0350]) strongly suggest that activation of the IFN induction cascade is not associated with 'normal' virus replication, which is perhaps not surprising considering the nuclear localisation of replication and the efficient encapsidation of full-length genomes. The link between the presence of 'abnormal' DI genomes and IFN induction by non-segmented negative-strand RNA viruses, including the Paramyxoviridae and Rhabdoviridae, is well known. DI genomes possess deletions that render a DI virus particle unable to complete a full replication cycle due to the absence of the coding region for one or more viral factor that is essential for replication; DI viruses are therefore only able to replicate when a co-infecting non-defective virus is present to supplement the missing viral factor/s. Furthermore, DIs interfere with the multiplication of non-defective virus by competing with non-DI genomes for replication and packaging (reviewed in [@bib0550]). Thus, although DI genomes are considered non-infectious in terms of their inability to generate viral progeny, they can still exert biological effects in host cells. In particular, IFN induction by paramyxoviruses and rhabdoviruses has been associated with 'copyback' or 'snapback' genome structures that are generated during template-switching of the viral RNA-dependent RNA polymerase between strands of opposite polarity ([@bib0035], [@bib0335], [@bib0405], [@bib0395], [@bib0530], [@bib0750], [@bib0765]). These structures possess often considerable stretches of dsRNA adjacent to a 5′ppp and are thus very effective RIG-I ligands ([@bib0035], [@bib0770]). Indeed, studies of IFN induction in single cells infected with a paramyxovirus lacking an IFN antagonist have indicated that the IFN-β promoter is not activated by the normal paramyxovirus life cycle, and that only DI-rich virus preparations activated the IFN-β promoter in a majority of cells ([@bib0405]). It is as yet unclear whether DI genomes themselves are responsible for inducing IFN, since they are encapsidated into stable nucleocapsids ([@bib0765]) and should therefore be hidden from recognition by RIG-I. DI-rich paramyxovirus preparations are potent activators of IRF3 even when progeny genome synthesis has been inhibited by cycloheximide ([@bib0400]); however, unlike the situation for influenza viruses, the requirements for RNA synthesis to IFN induction by paramyxovirus DI genomes cannot easily be studied using inhibitors of cellular transcription, so it remains to be determined whether input DI genomes are sufficient for this process.

Influenza virus readily generates DI genomes; DI influenza viruses were first identified in the 1950s as 'incomplete' non-infectious viruses that were selected for upon serial passage of the virus in embryonated chicken eggs at high multiplicity ([@bib0825], [@bib0830]) and they have been described in many studies since (reviewed in [@bib0130], [@bib0585]). In contrast to non-segmented negative-strand RNA viruses, copyback structures are not thought to be generated during influenza virus replication. Instead, influenza DI viruses appear to be limited to internal deletion RNAs that retain the 5′ and 3′ termini of genome segment from which they are derived. Influenza virus DIs can arise from all genome segments, but appear to be more readily detectable from PB2, PB1 and PA segments. The generation of DIs has long been thought of as an artificial laboratory/tissue-culture artefact in laboratory-prepared and egg-derived virus stocks, and their relevance to genuine virus infections *in vivo* has been questioned. However, several recent studies have suggested an important role for DIs in natural influenza virus infections and in disease outcome. Internal deletion DI viruses similar to those identified *in vitro* have been detected in samples from infected mice ([@bib0790]), poultry ([@bib0340]) and humans ([@bib0340], [@bib0700]). Furthermore, DIs are generated *de novo* during *in vivo* infections ([@bib0790]) and the transmission of DI viruses between human patients has been described ([@bib0700]). Evidence is accumulating for an important role of influenza virus DIs in IFN induction. Following a quantitative analysis of different subpopulations of an influenza virus, [@bib0535] concluded that IFN-inducing particles are not productively infectious. DI RNA was directly implicated in IFN induction by a study that identified subgenomic RNAs derived from PA and PB1 segments in RIG-I immunoprecipitates from influenza virus-infected cells ([@bib0035]). Subsequently, studies have correlated the IFN-inducing phenotype of influenza viruses with a propensity to generate or accumulate high numbers of DI genomes in tissue culture ([@bib0205], [@bib0595], [@bib0650]). Perez-Cidoncha and colleagues passaged influenza virus through IFN-resistant cells in order to select for mutants that were impaired in their ability to prevent IFN induction or signalling. By this method, a number of mutant viruses were obtained that were stronger IFN inducers than wild-type virus and several of these IFN-inducing mutants were found to accumulate large numbers of DI genomes in infected cells ([@bib0650]). We have studied the link between influenza virus DIs and IFN induction in tissue culture and found that a preparation of PR8 virus that has been passaged so as to enrich for DI content is a much more efficient activator of the IFN response than our starting virus stock, when cells are infected with either an equivalent amount of total virus particles or plaque-forming virus particles ([Fig. 4](#fig0020){ref-type="fig"}). Recent *in vivo* comparisons of the effects of DI-poor or DI-rich influenza virus preparations have shown that the presence of high numbers of DIs is associated with enhanced IFN-β expression in the lungs of infected mice and a reduction in animal morbidity ([@bib0790]). Moreover, a preparation of influenza virus composed of a single DI species generated by reverse genetics (a internal deletion DI derived from segment 1, [@bib0135]) protects mice against infections by heterologous influenza B virus and paramyxovirus infections ([@bib0150], [@bib0735]). This protection was impaired in mice lacking a functional type I IFN receptor, indicating that this protective effect is mediated at least in part by activation of the IFN response ([@bib0150], [@bib0735]). What remains unclear is why influenza virus DI RNAs should be more effective at inducing IFN than non-defective, full-length genome segments. Due to the requirements for certain sequences at each end of the genome segment for packaging into virions ([@bib0240]), internal deletion RNAs possess identical 5′ and 3′ termini to non-defective, full-length genomic RNAs and would not therefore be expected to differ in their inherent ability to bind RIG-I. The ability of DI viruses to induce IFN may simply be due to a faster replication rate of DI RNAs than full-length genomes because of their smaller size. Alternatively, DI-mediated interference with viral polymerase and NP expression may lead to a reduction in polymerase-imposed shut-off of cellular gene expression ([@bib0600]) or affect the efficiency of cRNA and vRNA encapsidation. Furthermore, DI-mediated interference may reduce NS1 expression, thereby contributing to IFN induction by limiting IFN antagonism by the virus. This occurs in DI-rich preparations of the paramyxovirus parainfluenza virus 5, where DIs simultaneously stimulate the IFN response and interfere with the expression of the V protein (the viral IFN antagonist) from co-infecting non-defective virus; as a result, the V protein only accumulates in infected cells after the IFN induction cascade has already been activated ([@bib0395]). Perhaps smaller segments of genomic RNA, such as the internal deletion RNAs and NS and M segment RNAs identified in RIG-I immunoprecipitates ([@bib0035]), form a panhandle more readily than full-length RNA when they are unencapsidated, or DI RNPs may be less stable than full-length RNPs and thus more prone to releasing free RNA. It is interesting to note that very small flu genome templates can be replicated in the absence of NP ([@bib0685], [@bib0810]); thus, it is a possibility that small DI RNAs could be replicated without being concurrently encapsidated and that these unencapsidated replication products could activate RIG-I.

8. Concluding remarks {#sec0040}
=====================

Innate immune responses, including the IFNs, play a critical role in determining the pathogenicity and outcome of an influenza virus infection: efficient activation of the IFN system early in infection effectively restricts viral replication and eliminates the virus, while excessive activation of innate immune responses actually increases tissue damage in the host. Here, we have outlined recent advances in the study of the IFN induction by influenza viruses and the identity of the PAMPs produced during influenza virus infection; however, several unanswered questions remain. Assuming the influenza virus panhandle is recognised by RIG-I during infection, it is unclear how this RNA structure is able to form in infected cells: if the panhandle is formed by free unencapsidated RNA, how and when in the virus life cycle is this RNA generated? Conversely, if the panhandle structure can be formed by RNA encapsidated into RNPs, how are the polymerase and/or NP displaced in order to expose the genome termini? What are the viral PAMPs that are generated in conditions when progeny genome synthesis has been blocked? What are the reasons for the cell-to-cell differences in activation of the IFN promoter during influenza virus infections *in vitro* and *in vivo*? Lastly, why are influenza DIs better able to induce IFN than non-defective virus? Multiple factors are likely to influence IFN induction by influenza virus during an infection, including the rate of virus replication, its ability to actively antagonise IFN induction, the rate of DI generation by the viral polymerase and also factors conferred by the host; by gaining a broader comprehension of all of these contributing elements, we can more fully understand the interactions between influenza virus and the IFN system and apply this understanding to the development of novel anti-influenza therapies.
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![Heterogeneity in activation of the IFN induction cascade in cells infected with influenza viruses. A549 cells expressing GFP under the control of an IFN-β promoter (A549/pr(IFN-β).GFP; [@bib0070]) were infected with 5 PFU/cell of PR8, Udorn or WSN strains of influenza A virus. Cells were left uninfected or infected with 5 PFU/cell Sendai virus (Cantell strain) as negative and positive controls for GFP expression respectively. At 16 h post-infection, monolayers fixed and stained with antibody raised against disrupted X31 virus and DAPI; GFP (green), viral protein expression (red) and cell nuclei (blue) were subsequently examined by confocal microscopy.](gr1){#fig0005}

![The panhandle and corkscrew structures of the influenza virus promoter. The panhandle (A) and corkscrew (B) conformations of influenza virus vRNA and the corkscrew conformation of cRNA (C) are shown. Sequences shown from segment 5 (NP) of the WSN strain of influenza virus.](gr2){#fig0010}

![Activation of the IFN induction cascade by influenza virus is sensitive to actinomycin D but not cycloheximide. A549 cells were infected with 5 PFU/cell of an NS1-defective Udorn virus (Ud-Δ99; [@bib1325]) or a DI-rich preparation of PIV5 (PIV5-VΔC vM2; [@bib0405]), in the presence of 1 μg/ml actinomycin D (ActD) or 50 μg/ml cycloheximide (CHX) or were left untreated (UT). At 16 h post-infection, cell lysates were prepared and probed for phospho-IRF3 (p-IRF3), total IRF3, viral proteins and actin.](gr3){#fig0015}

![DIs in influenza virus preparations correlate with an enhanced ability to activate the interferon system. DI-preparations of PR8 were obtained by four sequential high multiplicity passages of the vM0 virus through MDCK cells. The total number of virus particles (haemagglutination units; HAU) and the plaque-forming titre (plaque-forming units; PFU) were obtained by haemagglutination assay and plaque assay respectively. A549 cells expressing GFP under the control of an IFN-β promoter (A549/pr(IFN-β).GFP; [@bib0070]) were infected with the low DI (vM0) or DI-rich (vM4) preparations of PR8 at equivalent infectious titre (0.3 PFU/cell) or an equivalent number of total virus particles (1 × 10^4^ HAU/cell). At 16 h post-infection, cells were trypsinised, fixed and analysed by flow cytometry for GFP expression (A). Duplicate monolayers were harvested for immunoblotting (B); lysates were probed for markers of activation of the interferon system (phospho-IRF3, GFP and MxA), viral NP expression and actin (as a loading control). The IFN present in culture media was estimated by CPE-reduction bio-assay, and the relative units of IFN (RUI) for each condition are indicated beneath the immunoblot panels.](gr4){#fig0020}
